British healthcare firm GlaxoSmithKline has filed for US regulatory approval of its new type 2 diabetes drug albiglutide, which belongs to the same group of injectable GLP-1 receptor agonists as Byetta, Bydureon and Victoza .
GSK announced on Monday that it had submitted the once-weekly medication to the US Food and Drug Administration (FDA) for approval and confirmed that it also plans to seek European Union regulatory approval for the new product in 2013.
Albiglutide is one of a number of new drugs developed by GSK that it hopes will boost its product portfolio, but it is yet to be approved as a treatment for type 2 diabetes or any other indication anywhere in the world.
To read the original article: GSK seeks FDA approval for new GLP-1 agonist
